novocure-NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of$ 0.34. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -79.41%. A quarter ago, it was expected that this oncology drug developer would post a loss of$ 0.34 per share when it actually produced a loss of $0.28, delivering a surprise of 17.65%.Over the last four quarters, the company ha ...